80 299

Cited 49 times in

Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy

Authors
Kwon, SR; Lim, MJ; Suh, CH; Park, SG; Hong, YS; Yoon, BY; Kim, HA; Choi, HJ; Park, W
Citation
Rheumatology international, 32(8):2523-2527, 2012
Journal Title
Rheumatology international
ISSN
0172-81721437-160X
Abstract
(1) To compare the serum levels of Dickkopf-1 (DKK-1) and bone biomarkers in patients with ankylosing spondylitis (AS) and healthy controls. (2) To examine the effects of anti-tumor necrosis factor-α (TNF-α) therapy for 3 months on bone biomarkers in patients with AS. We measured the levels of DKK-1, osteocalcin, osteoprotegerin, and C-terminal telopeptide of type I collagen (CTX-1) in patients with AS and in healthy controls at baseline and 3 months after initiating anti-TNF-α therapy in AS patients. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores were also measured before and after anti-TNF-α therapy in AS patients. Serum levels of DKK-1 were significantly lower in the AS patients than in the controls (P < 0.0001). Osteocalcin and osteoprotegerin levels were significantly higher in the AS patients than in the controls (P < 0.0001). Serum levels of DKK-1 were not changed after the 3-month anti-TNF-α therapy. Osteocalcin level increased (P < 0.0001), osteoprotegerin level and BASDAI scores decreased (P = 0.025 and P < 0.0001, respectively) significantly after the 3-months anti-TNF-α therapy. Serum DKK-1 level was lower in patients with AS than in healthy controls and did not change after 3 months of anti-TNF-α therapy in the AS patients despite the marked improvement in BASDAI scores. These findings suggest the low serum DKK-1 level is related to the pathogenesis of new bone formation in AS, which is resistant to TNF-α blocking therapy.
MeSH terms
AdultAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, Humanized/therapeutic useBiological Markers/bloodCase-Control StudiesCollagen Type I/bloodDown-RegulationFemaleHumansImmunoglobulin G/therapeutic useImmunologic Factors/*therapeutic useIntercellular Signaling Peptides and Proteins/*bloodMaleMiddle AgedOsteocalcin/bloodOsteogenesis/drug effectsOsteoprotegerin/bloodPeptides/bloodReceptors, Tumor Necrosis Factor/therapeutic useRepublic of KoreaSeverity of Illness IndexSpondylitis, Ankylosing/*blood/diagnosis/*drug therapy/immunologyTime FactorsTreatment OutcomeTumor Necrosis Factor-alpha/*antagonists & inhibitors
DOI
10.1007/s00296-011-1981-0
PMID
21833531
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Rheumatology
AJOU Authors
서, 창희김, 현아
Files in This Item:
fulltext not available.txtDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse